ImmunityBio, Inc.
IBRX
$7.76
-$0.31-3.78%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -170.33% | -108.88% | 15.03% | 40.69% | 38.58% |
| Total Depreciation and Amortization | 1.23% | -5.06% | -12.13% | -12.14% | -9.98% |
| Total Amortization of Deferred Charges | -99.11% | -99.41% | -99.56% | -79.73% | -62.59% |
| Total Other Non-Cash Items | 1,775.68% | 1,252.87% | 5,199.32% | -62.76% | -77.46% |
| Change in Net Operating Assets | 42.96% | 12.70% | -179.73% | -47.87% | -54.98% |
| Cash from Operations | 19.57% | 20.47% | 22.06% | 24.13% | 14.74% |
| Capital Expenditure | 2.38% | 33.30% | 44.16% | 60.30% | 54.50% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -485.90% | -628.65% | -2,624.06% | -2,414.24% | 182.42% |
| Cash from Investing | -540.56% | -774.71% | -1,123.26% | -825.52% | 162.54% |
| Total Debt Issued | -- | -19.61% | -97.03% | -100.00% | -100.00% |
| Total Debt Repaid | -11,188.46% | -4,646.51% | -1,712.50% | 80.95% | 67.90% |
| Issuance of Common Stock | 44.75% | 216.10% | 110.71% | 395.24% | 156.23% |
| Repurchase of Common Stock | -206.70% | -187.75% | 58.55% | 60.19% | 64.46% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 68.78% | 131.17% | 42.12% | 20.53% | -50.71% |
| Foreign Exchange rate Adjustments | -2.86% | 2,350.00% | 165.22% | 106.98% | 227.27% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -894.33% | 301.21% | 55.30% | 22.78% | -91.10% |